

ANNEXURE-1

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Piramal Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	East Bridge Capital Master Fund Ltd. East Bridge Capital Master Fund I Ltd.		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	Bombay Stock Exchange Limited National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	0	0%	0%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
c) Voting rights (VR) otherwise than by equity shares	N.A.	N.A.	N.A.
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	N.A.	N.A.	N.A.
e) Total (a+b+c+d)	0	0%	0%
Details of acquisition			
a) Shares carrying voting rights acquired	67,075,608	5.62%	5.62%
b) VRs acquired otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	0	0%	0%

category) acquired			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
e) Total (a+b+c+/-d)	67,075,608	5.62%	5.62%
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	67,075,608	5.62%	5.62%
b) VRs otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
e) Total (a+b+c+d)	67,075,608	5.62%	5.62%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Pursuant to the Composite Scheme of Arrangement amongst Piramal Enterprises Ltd., Piramal Pharma Ltd., Convergence Chemical Private Ltd., Hemmo Pharmaceuticals Private Ltd., PHL Fininvest Private Ltd. and their respective Shareholders and Creditors ('Scheme') as approved by NCLT.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	19-Oct-2022		
Equity share capital / total voting capital of the TC before the said acquisition	11,933,185,000		
Equity share capital/ total voting capital of the TC after the said acquisition	11,933,185,000		
Total diluted share/voting capital of the TC after the said acquisition	11,933,185,000		

Part-B***

Signature of the acquirer / Authorised Signatory



Place: *Boston, MA*

Date: *Oct 30, 2022*

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.